The results indicated that ALG3 was significantly upregulated in several malignancies, including hepatocellular carcinoma (HCC), bladder cancer, breast cancer, cervical squamous cell carcinoma, cholangiocarcinoma, colon adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, glioblastoma, lung adenocarcinoma, lung squamous carcinoma, prostate adenocarcinoma, rectal adenocarcinoma, gastric adenocarcinoma, and endometrial carcinoma. Here, ALG3 is linked to breast carcinoma.